Rothschild Investment LLC Sells 13,792 Shares of Pfizer Inc. (NYSE:PFE)

Rothschild Investment LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 9.7% during the 1st quarter, HoldingsChannel.com reports. The fund owned 128,416 shares of the biopharmaceutical company’s stock after selling 13,792 shares during the period. Rothschild Investment LLC’s holdings in Pfizer were worth $3,254,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Welch Group LLC increased its stake in Pfizer by 76.9% in the 1st quarter. Welch Group LLC now owns 1,826,932 shares of the biopharmaceutical company’s stock worth $46,057,000 after buying an additional 794,076 shares during the period. Parallel Advisors LLC grew its stake in Pfizer by 5.8% in the 1st quarter. Parallel Advisors LLC now owns 100,593 shares of the biopharmaceutical company’s stock worth $2,549,000 after acquiring an additional 5,547 shares in the last quarter. Tompkins Financial Corp increased its position in shares of Pfizer by 44.6% during the first quarter. Tompkins Financial Corp now owns 61,795 shares of the biopharmaceutical company’s stock worth $1,566,000 after acquiring an additional 19,059 shares during the period. GAMMA Investing LLC raised its stake in shares of Pfizer by 4,183.6% during the first quarter. GAMMA Investing LLC now owns 1,599,742 shares of the biopharmaceutical company’s stock valued at $40,537,000 after acquiring an additional 1,562,396 shares in the last quarter. Finally, AdvisorNet Financial Inc boosted its holdings in shares of Pfizer by 7.7% in the first quarter. AdvisorNet Financial Inc now owns 46,612 shares of the biopharmaceutical company’s stock valued at $1,181,000 after purchasing an additional 3,341 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.0%

NYSE:PFE opened at $23.46 on Friday. The company’s 50-day simple moving average is $23.12 and its 200-day simple moving average is $25.07. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The stock has a market capitalization of $133.38 billion, a P/E ratio of 16.64, a P/E/G ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the firm earned $0.82 earnings per share. Pfizer’s revenue was down 7.8% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.33%. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Wall Street Analyst Weigh In

Several research analysts have commented on PFE shares. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group raised their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price on the stock. Finally, Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.